Procter & Gamble Health Ltd
Pharmaceuticals & Biotechnology | Small Cap
Procter & Gamble Health Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company demonstrates strengths in solvency and efficiency, particularly in managing inventory and receivables. However, it faces significant challenges in liquidity, growth, coverage, profitability, and key financial metrics such as earnings per share and margins. Capital expenditure management appears to be a notable positive aspect. The company's overall financial health suggests a need for improvement in several areas to ensure sustainable growth and stability. While it effectively handles some operational aspects, addressing weaknesses in profitability and liquidity will be crucial for future success.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.00
- Financial Ratio3.60
- Profitability Ratio2.00
- Efficiency Ratio4.67
- Coverage Ratio2.00
- Solvency Ratio8.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentStrong
- Risk AssessmentStrong
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekBullish
- 1 MonthBullish
Procter & Gamble Health Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company demonstrates strengths in solvency and efficiency, particularly in managing inventory and receivables. However, it faces significant challenges in liquidity, growth, coverage, profitability, and key financial metrics such as earnings per share and margins. Capital expenditure management appears to be a notable positive aspect. The company's overall financial health suggests a need for improvement in several areas to ensure sustainable growth and stability. While it effectively handles some operational aspects, addressing weaknesses in profitability and liquidity will be crucial for future success.
Overall Valuation Score
P/E RATIO (TTM)
31.71
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
31.71
P/B RATIO
19.76
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
7.27
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
21.19
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹6244 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The growth performance is weak across all metrics, indicating limited expansion and potential stagnation. This could stem from market saturation, competitive pressures, or ineffective growth strategies. The company may face challenges in attracting investors and maintaining market share. Focus on innovation and strategic investments is crucial to revitalize growth prospects and ensure long-term sustainability. The company needs to improve its growth prospects.
| Growth Ratios | Jun 2020 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2025 16m |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth Rate | ||||||||
| Operating Profit Growth Rate | ||||||||
| Earnings Per Share (EPS) Growth | ||||||||
| Asset Growth Rate | ||||||||
| Net Income Growth Rate |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial metrics present a mixed picture. While capital expenditures are well-managed, earnings per share, book value, and dividends per share need improvement. Enhancing profitability and shareholder value is crucial for attracting investors and ensuring long-term financial health. The company needs to improve its earnings and dividends.
| Financial Ratios | Jun 2020 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2025 16m |
|---|---|---|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | ||||||||
| Cash Earnings Per Share (Cash EPS) | ||||||||
| Book Value Per Share | ||||||||
| Dividend Per Share (DPS) | ||||||||
| Capital Expenditures (CapEx) |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The profitability metrics indicate that the company is struggling to generate profits. This could be due to high costs, pricing pressures, or inefficient operations. Improving cost management and operational efficiency are crucial to enhance profitability and ensure sustainable financial performance. The company needs to improve its profitability.
| Profitability Ratios | Jun 2020 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2025 16m |
|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | ||||||||
| Return on Capital Employed (ROCE) | ||||||||
| Return on Equity (ROE) | ||||||||
| Return on Assets (ROA) | ||||||||
| Operating Margin | ||||||||
| Net Margin |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company demonstrates mixed efficiency. While it excels in managing inventory and receivables, it struggles in fixed asset and capital turnover. This suggests effective working capital management but inefficient use of long-term assets. Improving asset utilization could enhance overall operational performance and profitability, ensuring better returns on investments. The company is doing well in short term assets but needs to improve long term assets.
| Efficiency Ratios | Jun 2020 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2025 16m |
|---|---|---|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | ||||||||
| Inventory Turnover Ratio | ||||||||
| Receivables Turnover Ratio | ||||||||
| Days Sales in Inventory Ratio | ||||||||
| Receivable Days | ||||||||
| Capital Turnover Ratio |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The coverage metrics indicate a limited capacity to meet interest and dividend obligations. This may raise concerns among investors and creditors about the company's financial resilience. Strengthening earnings and optimizing capital structure are essential to improve coverage ratios and ensure financial stability. The company is not able to cover its interest and dividend payments.
| Coverage Ratios | Jun 2020 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2025 16m |
|---|---|---|---|---|---|---|---|---|
| Interest Coverage Ratio | ||||||||
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits a strong solvency position, with the ability to meet its long-term obligations. This financial stability can provide a buffer during economic downturns and allow for strategic investments. However, the company should monitor its debt and equity levels to maintain a balanced capital structure, ensuring sustainable growth and shareholder value. This indicates long term stability and ability to remain solvent.
| Solvency Ratios | Jun 2020 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2025 16m |
|---|---|---|---|---|---|---|---|---|
| Debt Ratio | ||||||||
| Debt to Equity Ratio | ||||||||
| Equity Ratio | ||||||||
| Debt To Asset Ratio |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The liquidity position indicates potential difficulties in meeting short-term obligations. While the company might be managing its assets, the inability to convert them quickly into cash raises concerns about financial flexibility. This could impact the company's ability to respond to unforeseen expenses or investment opportunities. The weighted average calculation, emphasizing recent performance, underscores the need for improved short-term asset management.
| Liquidity Ratios | Jun 2020 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2025 16m |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | ||||||||
| Quick Ratio | ||||||||
| Cash Ratio | ||||||||
| Operating Cash Flow Ratio |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Granules India Ltd | 7.73 | 32.77 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 2 | FDC Ltd | 7.64 | 22.52 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 35.90 | Neutral | 369.00 | 19.44 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 38.55 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 37.30 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Marksans Pharma Ltd | 7.24 | 28.16 | Neutral | 601.00 | 6.64 | 420.00 |
| 8 | Hikal Ltd | 7.13 | -51.71 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | Shilpa Medicare Ltd | 5.94 | 44.32 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 10 | Strides Pharma Science Ltd | 5.55 | 18.41 | Undervalued | 925.00 | 19.92 | 575.00 |
| 11 | Jeena Sikho Lifecare Ltd | 5.52 | 31.22 | Neutral | 349.00 | 17.87 | 222.00 |
| 12 | Aarti Drugs Ltd | 5.07 | 17.34 | Undervalued | 309.00 | 18.54 | 195.00 |
| 13 | Orchid Pharma Ltd | 4.85 | 241.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 14 | Sequent Scientific Ltd | 4.61 | 293.05 | Overvalued | 162.00 | 0.63 | 32.00 |
| 15 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.97 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 16 | Zota Health Care Ltd | 3.97 | -61.25 | Neutral | 19.00 | 8.06 | -74.00 |
| 17 | Procter & Gamble Health Ltd | 3.45 | 31.71 | Neutral | 457.00 | 196.94 | 327.00 |
| 18 | Sanofi India Ltd | 3.45 | 18.59 | Neutral | 491.00 | 134.52 | 413.00 |
Procter & Gamble Health Ltd demonstrates effective management through consistent profitability, efficient capital use, and a stable ownership structure. The company exhibits strong returns on shareholder funds. Prudent financial management is reflected in minimal debt. High promoter holding indicates confidence and alignment. Management effectively maintains a strong financial position and delivers shareholder value.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | ROCE | 45% | Effective use of capital |
| ROE | 33% | Strong returns on shareholder funds | |
| CONS | YOY Sales Growth % | -6.37% | Indicates some inconsistency in revenue expansion |
| Dividend Payout (%) | 215% | High dividend payout ratio |
Financial Performance & Growth
Procter & Gamble Health Ltd demonstrates good financial performance and growth, as evidenced by its revenue and profit expansion. Sales Growth shows a stable trajectory. The OPM % has improved, indicating increased operational efficiency. Net profit remains consistent. The company's performance is primarily driven by core operations rather than other income. YOY Sales Growth % shows volatility, indicating inconsistent revenue expansion.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Compounded Sales Growth (%) | 7.5% | 13.46% | 10.3% | 10.34% | -6.37% |
| Compounded Profit Growth (%) | 56.7% | 158.3% | -25.2% | 229 | 201 |
Capital Efficiency & Returns
Procter & Gamble Health Ltd showcases excellent capital efficiency and returns, as reflected in its ROCE and ROE figures. The ROCE % has consistently remained high, indicating effective use of capital. The ROE % also exhibits strong returns on shareholder funds. The company demonstrates efficient conversion of assets into revenue through its asset turnover ratio. The cash conversion cycle indicates efficient working capital management.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| ROCE (%) | 15% | 37% | 29% | 38% | 45% | 45% |
| ROE (%) | 28% | 27% | 30% | 32% | 32% | 33% |
Financial Health & Prudence
The company exhibits excellent financial health and prudence. Debt levels are minimal, as indicated by low borrowings and debt-to-equity ratio. The interest coverage ratio demonstrates the company's ability to comfortably cover its interest obligations. The company consistently shares profits with shareholders through dividend payouts. The overall financial structure is stable and well-managed.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Debt/Equity Ratio | 0 | 0 | 0.02 | 0.01 | 0.02 | 0.02 |
| Dividend Payout (%) | 23.67% | 36.33% | 57% | 45% | 69% | 215% |
Strategic & Operational Indicators
Procter & Gamble Health Ltd. demonstrates strategic and operational efficiency. Operational cycles are managed efficiently, as reflected in debtor days, inventory days, and payable days. The company strategically invests in fixed assets for growth. Working capital management is effective, ensuring smooth operations.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Debtor Days | 43.67 | 43.67 | 26.33 | 27 | 34 | 27 |
| Inventory Days | 145 | 177.33 | 130 | 124 | 136 | 120 |
The risk assessment for Procter & Gamble Health Ltd. indicates a low-risk profile. There are no identified off-balance sheet exposures or accounting quality red flags. Segment performance is reasonably stable. The company maintains regulatory compliance. The overall risk profile is positive, reflecting strong financial management and operational stability.
Off-balance sheet exposure quantification
There is no off-balance sheet exposure.
Contingent liability evaluation
There is no contingent liability.
Accounting quality red flags
Accounting quality is good.
Segment performance volatility
There is no segment performance volatility.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 106293.50Bullish
- SMA 206267.88Bullish
- SMA 506248.78Bullish
- EMA 106281.71Bullish
- EMA 206272.09Bullish
- EMA 506244.25Bullish
- DEMA 106288.38Bullish
- DEMA 206290.02Bullish
- DEMA 506302.48Bullish
- TEMA 106282.71Bullish
- TEMA 206293.77Bullish
- TEMA 506268.30Bullish
- MACD13.25Bearish
- ADX14.52Weak Trend
- IndicatorValueSignal
- RSI58.76Neutral
- CCI45.07Neutral
- ROC 90.90Bullish
- ROC 141.61Bullish
- ROC 251.47Bullish
- Stoch K32.77Neutral
- Stoch D29.01Neutral
- IndicatorValueSignal
- BB Upper6349.59Neutral
- BB Middle6267.88Neutral
- BB Lower6186.16Neutral
- ATR46.12High Volatility
- IndicatorValueSignal
- MFI66.60Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 106278.25Bullish
- SMA 206254.82Bullish
- SMA 506231.26Bullish
- EMA 106278.35Bullish
- EMA 206261.84Bullish
- EMA 506182.18Bullish
- DEMA 106295.78Bullish
- DEMA 206291.99Bullish
- DEMA 506361.33Bearish
- TEMA 106299.18Bullish
- TEMA 206286.26Bullish
- TEMA 506309.59Bullish
- MACD23.24Bullish
- ADX21.01Weak Trend
- IndicatorValueSignal
- RSI58.33Neutral
- CCI73.66Neutral
- ROC 91.12Bullish
- ROC 141.52Bullish
- ROC 251.73Bullish
- Stoch K45.82Neutral
- Stoch D56.19Neutral
- IndicatorValueSignal
- BB Upper6332.27Neutral
- BB Middle6254.83Neutral
- BB Lower6177.38Neutral
- ATR62.90High Volatility
- IndicatorValueSignal
- MFI62.68Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 106250.95Bullish
- SMA 206235.90Bullish
- SMA 505956.60Bullish
- EMA 106260.06Bullish
- EMA 206212.86Bullish
- EMA 505979.87Bullish
- DEMA 106291.68Bullish
- DEMA 206331.02Bearish
- DEMA 506362.26Bearish
- TEMA 106289.63Bullish
- TEMA 206281.46Bullish
- TEMA 50N/AN/A
- MACD81.42Bearish
- ADX47.26Strong Trend
- IndicatorValueSignal
- RSI63.99Neutral
- CCI110.06Overbought
- ROC 91.42Bullish
- ROC 141.24Bullish
- ROC 254.26Bullish
- Stoch K64.67Neutral
- Stoch D60.40Neutral
- IndicatorValueSignal
- BB Upper6314.47Overbought
- BB Middle6235.90Neutral
- BB Lower6157.33Neutral
- ATR96.19High Volatility
- IndicatorValueSignal
- MFI39.01Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 106235.40Bullish
- SMA 206072.35Bullish
- SMA 505510.25Bullish
- SMA 1005288.22Bullish
- SMA 2005634.21Bullish
- EMA 106206.02Bullish
- EMA 206040.82Bullish
- EMA 505680.74Bullish
- EMA 1005522.80Bullish
- EMA 2005523.33Bullish
- DEMA 106332.15Bearish
- DEMA 206361.80Bearish
- DEMA 506035.72Bullish
- DEMA 1005601.94Bullish
- DEMA 2005502.36Bullish
- TEMA 106287.59Bullish
- TEMA 206397.11Bearish
- TEMA 506344.69Bearish
- TEMA 1005831.94Bullish
- TEMA 2005437.22Bullish
- MACD231.87Bearish
- ADX57.66Strong Trend
- IndicatorValueSignal
- RSI72.67Overbought
- CCI72.82Neutral
- ROC 144.20Bullish
- ROC 2520.89Bullish
- Stoch K68.98Neutral
- Stoch D60.40Neutral
- IndicatorValueSignal
- BB Upper6577.54Neutral
- BB Middle6072.35Neutral
- BB Lower5567.16Neutral
- ATR151.45Low Volatility
- IndicatorValueSignal
- MFI43.58Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 205235.50Bullish
- SMA 505680.51Bullish
- EMA 205489.34Bullish
- EMA 505497.68Bullish
- DEMA 205578.15Bullish
- DEMA 505490.05Bullish
- TEMA 205813.30Bullish
- TEMA 505388.34Bullish
- MACD118.31Bullish
- ADX31.95Strong Trend
- IndicatorValueSignal
- RSI66.25Neutral
- CCI82.76Neutral
- ROC 1428.63Bullish
- ROC 2511.04Bullish
- Stoch K73.96Neutral
- Stoch D74.62Neutral
- IndicatorValueSignal
- BB Upper6125.20Overbought
- BB Middle5235.50Neutral
- BB Lower4345.80Neutral
- ATR324.20Low Volatility
- IndicatorValueSignal
- MFI92.22Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 65329.70Bullish
- SMA 125693.39Bullish
- SMA 245471.05Bullish
- EMA 65490.19Bullish
- EMA 125505.02Bullish
- EMA 245429.03Bullish
- DEMA 65491.02Bullish
- DEMA 125518.09Bullish
- DEMA 245629.79Bullish
- TEMA 65579.57Bullish
- TEMA 125425.68Bullish
- TEMA 245593.65Bullish
- MACD328.21Bearish
- ADX26.86Strong Trend
- IndicatorValueSignal
- RSI57.44Neutral
- CCI131.51Overbought
- ROC 2523.35Bullish
- ROC 5051.31Bullish
- Stoch K54.32Neutral
- Stoch D60.44Neutral
- IndicatorValueSignal
- BB Upper6451.27Neutral
- BB Middle5518.07Neutral
- BB Lower4584.86Neutral
- ATR616.90High Volatility
- IndicatorValueSignal
- MFI66.29Neutral